{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:08:05Z","timestamp":1789596485021,"version":"build-2803163510"},"reference-count":153,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004881","name":"Instituto Mexicano del Seguro Social","doi-asserted-by":"publisher","award":["R-2015-785-008"],"award-info":[{"award-number":["R-2015-785-008"]}],"id":[{"id":"10.13039\/501100004881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009609","name":"Fondo de Apoyo a la investigaci\u00f3n, Hospital Infantil de M\u00e9xico Federico G\u00f3mez","doi-asserted-by":"publisher","award":["HIM-2014-053"],"award-info":[{"award-number":["HIM-2014-053"]}],"id":[{"id":"10.13039\/501100009609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004881","name":"Instituto Mexicano del Seguro Social","doi-asserted-by":"publisher","award":["R\u20102015\u2010785\u2010008"],"award-info":[{"award-number":["R\u20102015\u2010785\u2010008"]}],"id":[{"id":"10.13039\/501100004881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009609","name":"Hospital Infantil de M\u00e9xico Federico G\u00f3mez","doi-asserted-by":"publisher","award":["HIM\u20102014\u2010053"],"award-info":[{"award-number":["HIM\u20102014\u2010053"]}],"id":[{"id":"10.13039\/501100009609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Melanoma is the deadliest form of skin cancer. Cutaneous melanomas usually originate from exposure to the mutagenic effects of ultraviolet radiation, and as such they exhibit the highest rate of somatic mutations than any other human cancer, and an extensive expression of neoantigens concurrently with a dense infiltrate of immune cells. The coexistence of high immunogenicity and high immune cell infiltration may sound contradictory for cancers carrying a gloomy outcome. However, recent studies have unveiled a variety of immunosuppressive mechanisms that often permeate the tumor microenvironment and that are responsible for tumor escaping from immunosurveillance mechanisms. Nonetheless, this particular immune profile has opened a new window of treatments based on immunotherapy that have significantly improved the clinical outcome of melanoma patients. Still, positive and complete therapy responses have been limited, and this particular cancer continues to be a major clinical challenge. The transcriptomic signatures of those patients with clinical benefit and those with progressive disease have provided a more complete picture of the universe of interactions between the tumor and the immune system. In this review, we integrate the results of the immunotherapy clinical trials to discuss a novel understanding of the mechanisms guiding cancer immunosurveillance and immunoediting. A clear notion of the cellular and molecular processes shaping how the immune system and the tumor are continuously coevolving would result in the rational design of combinatory therapies aiming to counteract the signaling pathways and cellular processes responsible for immunoescape mechanisms and provide clinical benefit to immunotherapy nonresponsive patients.<\/jats:p>","DOI":"10.1002\/jlb.mr0618-241rr","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T18:52:46Z","timestamp":1548874366000},"page":"915-933","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy"],"prefix":"10.1093","volume":"105","author":[{"given":"Ricardo A","family":"Le\u00f3n-Letelier","sequence":"first","affiliation":[{"name":"Hospital de Especialidades, Centro M\u00e9dico Nacional Siglo XXI, Unidad de Investigaci\u00f3n M\u00e9dica en Inmunoqu\u00edmica , Ciudad de M\u00e9xico, M\u00e9xico"},{"name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM) , M\u00e9xico Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Bonifaz","sequence":"additional","affiliation":[{"name":"Hospital de Especialidades, Centro M\u00e9dico Nacional Siglo XXI, Unidad de Investigaci\u00f3n M\u00e9dica en Inmunoqu\u00edmica , Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel M","family":"Fuentes-Panan\u00e1","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n en Virolog\u00eda y C\u00e1ncer, Hospital Infantil de M\u00e9xico Federico G\u00f3mez , Ciudad de M\u00e9xico, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"2023032406175412500_jlb10322-cit-0001","first-page":"1","volume-title":"Cancer facts and figures 2017?","author":"ACS","year":"2017"},{"key":"2023032406175412500_jlb10322-cit-0002","author":"SEER"},{"key":"2023032406175412500_jlb10322-cit-0003","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma?","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"2023032406175412500_jlb10322-cit-0004","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer?","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2023032406175412500_jlb10322-cit-0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fonc.2018.00027","article-title":"The expression and prognostic impact of immune cytolytic activity-related markers in human malignancies: a comprehensive meta-analysis?","volume":"8","author":"Roufas","year":"2018","journal-title":"Front Oncol"},{"key":"2023032406175412500_jlb10322-cit-0006","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The immune landscape of cancer?","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"2023032406175412500_jlb10322-cit-0007","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases?","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Cancer"},{"key":"2023032406175412500_jlb10322-cit-0008","first-page":"3399","article-title":"A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice?","volume":"61","author":"Nakajima","year":"2001","journal-title":"Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0009","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1073\/pnas.95.13.7556","article-title":"Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice?","volume":"95","author":"Kaplan","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032406175412500_jlb10322-cit-0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/1074-7613(94)90087-6","article-title":"Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN\u03b3 receptors?","volume":"1","author":"Dighe","year":"1994","journal-title":"Immunity"},{"key":"2023032406175412500_jlb10322-cit-0011","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103+\/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma?","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"2023032406175412500_jlb10322-cit-0012","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nri3712","article-title":"Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny?","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"2023032406175412500_jlb10322-cit-0013","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells?","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"key":"2023032406175412500_jlb10322-cit-0014","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity?","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"key":"2023032406175412500_jlb10322-cit-0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells?","volume":"6","author":"Sanchez-Paulete","year":"2016","journal-title":"Cancer Discov"},{"key":"2023032406175412500_jlb10322-cit-0016","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control?","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"2023032406175412500_jlb10322-cit-0017","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8 dendritic cells in cytotoxic T cell immunity?","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"2023032406175412500_jlb10322-cit-0018","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition?","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"key":"2023032406175412500_jlb10322-cit-0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-04607-9","article-title":"Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer?","volume":"9","author":"Nam","year":"2018","journal-title":"Nat Commun"},{"key":"2023032406175412500_jlb10322-cit-0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.immuni.2018.03.004","article-title":"Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape?","volume":"48","author":"Wellenstein","year":"2018","journal-title":"Immunity"},{"key":"2023032406175412500_jlb10322-cit-0021","article-title":"Classification of current anticancer immunotherapies?","volume":"2014","author":"Galluzzi","year":"2014","journal-title":"Oncotarget"},{"key":"2023032406175412500_jlb10322-cit-0022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","article-title":"A molecular perspective of CTLA-4 function?","volume":"24","author":"Teft","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"2023032406175412500_jlb10322-cit-0023","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways?","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"2023032406175412500_jlb10322-cit-0024","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1146\/annurev.immunol.19.1.565","article-title":"CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy?","volume":"19","author":"Chambers","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"2023032406175412500_jlb10322-cit-0025","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s00262-016-1906-6","article-title":"Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model?","volume":"65","author":"Dyck","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2023032406175412500_jlb10322-cit-0026","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma?","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"2023032406175412500_jlb10322-cit-0027","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.172.4.2352","article-title":"Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains?","volume":"172","author":"Steinberger","year":"2004","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0028","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","article-title":"B7-H3: a costimulatory molecule for T cell activation and IFN-\u03b3 production?","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat Immunol"},{"key":"2023032406175412500_jlb10322-cit-0029","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/eji.200636841","article-title":"Induction of immunosuppressive functions of dendritic cellsin vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation?","volume":"37","author":"Mahnke","year":"2007","journal-title":"Eur J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0030","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","article-title":"Murine B7-H3 Is a Negative Regulator of T Cells?","volume":"173","author":"Prasad","year":"2004","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0031","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yexcr.2012.09.006","article-title":"Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response?","volume":"319","author":"Chen","year":"2013","journal-title":"Exp Cell Res"},{"key":"2023032406175412500_jlb10322-cit-0032","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/jid.2013.114","article-title":"B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma?","volume":"133","author":"Wang","year":"2013","journal-title":"J Investig Dermatol"},{"key":"2023032406175412500_jlb10322-cit-0033","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2174\/156800908785133141","article-title":"The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion?","volume":"8","author":"Chen","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"2023032406175412500_jlb10322-cit-0034","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.4049\/jimmunol.1300271","article-title":"Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma?","volume":"190","author":"Goding","year":"2013","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0035","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors?","volume":"124","author":"Gros","year":"2014","journal-title":"J Clin Invest"},{"key":"2023032406175412500_jlb10322-cit-0036","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1126\/science.1148536","article-title":"Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells?","volume":"318","author":"Anderson","year":"2007","journal-title":"Science"},{"key":"2023032406175412500_jlb10322-cit-0037","doi-asserted-by":"crossref","first-page":"e58006","DOI":"10.1371\/journal.pone.0058006","article-title":"Tim-3 expression defines regulatory T cells in human tumors?","volume":"8","author":"Yan","year":"2013","journal-title":"PLoS ONE"},{"key":"2023032406175412500_jlb10322-cit-0038","doi-asserted-by":"crossref","first-page":"e23849","DOI":"10.4161\/onci.23849","article-title":"TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer?","volume":"2","author":"Sakuishi","year":"2013","journal-title":"OncoImmunology"},{"key":"2023032406175412500_jlb10322-cit-0039","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity?","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"key":"2023032406175412500_jlb10322-cit-0040","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen\u2013specific CD8 +T cell dysfunction in melanoma patients?","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"2023032406175412500_jlb10322-cit-0041","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/eji.200323382","article-title":"The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells?","volume":"33","author":"Workman","year":"2003","journal-title":"Eur J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0042","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.4049\/jimmunol.161.8.4058","article-title":"CD3\/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3\/TCR signaling?","volume":"161","author":"Hannier","year":"1998","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0043","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells?","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"2023032406175412500_jlb10322-cit-0044","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice?","volume":"208","author":"Okazaki","year":"2011","journal-title":"J Exp Med"},{"key":"2023032406175412500_jlb10322-cit-0045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape?","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0046","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","article-title":"The interaction between signal regulatory protein alpha (SIRP \u03b1) and CD47: structure, function, and therapeutic target?","volume":"32","author":"Barclay","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"2023032406175412500_jlb10322-cit-0047","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.4049\/jimmunol.1102702","article-title":"CD47(high) expression on CD4 effectors identifies functional long-lived memory T cell progenitors?","volume":"188","author":"Van","year":"2012","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0048","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response?","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032406175412500_jlb10322-cit-0049","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.biopha.2017.06.030","article-title":"High expression of CD47 predicts adverse prognosis in Chinese patients and suppresses immune response in melanoma?","volume":"93","author":"Fu","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2023032406175412500_jlb10322-cit-0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.89140","article-title":"Anti-SIRP\u03b1 antibodies as a potential new tool for cancer immunotherapy?","volume":"2","author":"Yanagita","year":"2017","journal-title":"JCI Insight"},{"key":"2023032406175412500_jlb10322-cit-0051","doi-asserted-by":"crossref","first-page":"10184","DOI":"10.1073\/pnas.1710776114","article-title":"Localized CD47 blockade enhances immunotherapy for murine melanoma?","volume":"114","author":"Ingram","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032406175412500_jlb10322-cit-0052","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0161-5890(00)00079-1","article-title":"Role for CD40-CD40 ligand interactions in the immune response to solid tumours?","volume":"37","author":"Alexandroff","year":"2000","journal-title":"Mol Immunol"},{"key":"2023032406175412500_jlb10322-cit-0053","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.4049\/jimmunol.170.5.2727","article-title":"Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses?","volume":"170","author":"Murphy","year":"2003","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0054","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1158\/2326-6066.CIR-14-0226","article-title":"Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment?","volume":"3","author":"Zippelius","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"2023032406175412500_jlb10322-cit-0055","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.20050940","article-title":"Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells?","volume":"202","author":"Ko","year":"2005","journal-title":"J Exp Med"},{"key":"2023032406175412500_jlb10322-cit-0056","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00262-010-0866-5","article-title":"Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy?","volume":"59","author":"Coe","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"2023032406175412500_jlb10322-cit-0057","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1084\/jem.20050940","article-title":"Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 +CD25 +CD4 +regulatory T cells?","volume":"202","author":"Ko","year":"2005","journal-title":"J Exp Med"},{"key":"2023032406175412500_jlb10322-cit-0058","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.4049\/jimmunol.176.11.6434","article-title":"Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance\/ignorance to melanoma differentiation antigens and enhances antitumor immunity?","volume":"176","author":"Ramirez-Montagut","year":"2006","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0059","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/2326-6066.CIR-13-0086","article-title":"GITR pathway activation abrogates tumor immune suppression through loss of regulatory T-cell lineage stability?","volume":"1","author":"Schaer","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"2023032406175412500_jlb10322-cit-0060","first-page":"2546","article-title":"Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy?","volume":"63","author":"Li","year":"2003","journal-title":"Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0061","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-1-3","article-title":"Essential complicity of perforin-granzyme and FAS-L mechanisms to achieve tumor rejection following treatment with anti-CD137 mAb?","volume":"1","author":"Morales-Kastresana","year":"2013","journal-title":"J ImmunoTher Cancer"},{"key":"2023032406175412500_jlb10322-cit-0062","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1084\/jem.186.1.47","article-title":"4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses?","volume":"186","author":"Shuford","year":"1997","journal-title":"J Exp Med"},{"key":"2023032406175412500_jlb10322-cit-0063","doi-asserted-by":"crossref","first-page":"e19499","DOI":"10.1371\/journal.pone.0019499","article-title":"Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production?","volume":"6","author":"Curran","year":"2011","journal-title":"PLoS ONE"},{"key":"2023032406175412500_jlb10322-cit-0064","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.4049\/jimmunol.179.3.1427","article-title":"Cutting edge: OX40 inhibits TGFb and antigen-driven conversion of naive CD4 t cells into CD25+Foxp3+ T cells?","volume":"179","author":"So","year":"2007","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0065","doi-asserted-by":"crossref","first-page":"e70635","DOI":"10.1371\/journal.pone.0070635","article-title":"Regulation of A1 by OX40 contributes to CD8+ T cell survival and anti-tumor activity?","volume":"8","author":"Lei","year":"2013","journal-title":"PLoS ONE"},{"key":"2023032406175412500_jlb10322-cit-0066","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1084\/jem.20071341","article-title":"OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection?","volume":"205","author":"Piconese","year":"2008","journal-title":"J Exp Med"},{"key":"2023032406175412500_jlb10322-cit-0067","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1084\/jem.20082205","article-title":"OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis?","volume":"206","author":"Hirschhorn-Cymerman","year":"2009","journal-title":"J Exp Med"},{"key":"2023032406175412500_jlb10322-cit-0068","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.4049\/jimmunol.1000159","article-title":"The Pim kinase pathway contributes to survival signaling in primed CD8+ T cells upon CD27 costimulation?","volume":"185","author":"Peperzak","year":"2010","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0069","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.immuni.2011.04.020","article-title":"The costimulatory molecule CD27 maintains clonally diverse CD8+ T cell responses of low antigen affinity to protect against viral variants?","volume":"35","author":"van Gisbergen","year":"2011","journal-title":"Immunity"},{"key":"2023032406175412500_jlb10322-cit-0070","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-065X.2009.00774.x","article-title":"Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology?","volume":"229","author":"Nolte","year":"2009","journal-title":"Immunol Rev"},{"key":"2023032406175412500_jlb10322-cit-0071","doi-asserted-by":"crossref","first-page":"djw144","DOI":"10.1093\/jnci\/djw144","article-title":"Genomic analysis of immune cell infiltrates across 11 tumor types?","volume":"108","author":"Iglesia","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2023032406175412500_jlb10322-cit-0072","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/CJI.0b013e3181ee238f","article-title":"Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and Reduced PD-1 expression of tumor infiltrating CD8+ T cells?","volume":"33","author":"Roberts","year":"2010","journal-title":"J Immunother"},{"key":"2023032406175412500_jlb10322-cit-0073","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.4049\/jimmunol.180.6.3739","article-title":"CD27 defines phenotypically and functionally different human NK cell subsets?","volume":"180","author":"Vossen","year":"2008","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0074","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.4049\/jimmunol.1202222","article-title":"CD8+ T cells produce the chemokine CXCL10 in response to CD27\/CD70 costimulation to promote generation of the CD8+ effector T cell pool?","volume":"191","author":"Peperzak","year":"2013","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0075","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.4049\/jimmunol.181.2.1071","article-title":"CD27 instructs CD4+ T cells to provide help for the memory CD8+ T cell response after protein immunization?","volume":"181","author":"Xiao","year":"2008","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0076","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma?","volume":"33","author":"Schadendorf","year":"2015","journal-title":"JCO"},{"key":"2023032406175412500_jlb10322-cit-0077","volume-title":"FDA approves ipilimumab for pediatric melanomaat","author":"Broderick","year":"2017"},{"key":"2023032406175412500_jlb10322-cit-0078","doi-asserted-by":"crossref","first-page":"5661","DOI":"10.1158\/1078-0432.CCR-16-0664","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma?","volume":"23","author":"Barone","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0079","first-page":"1","year":"2015"},{"key":"2023032406175412500_jlb10322-cit-0080","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma?","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2023032406175412500_jlb10322-cit-0081","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial?","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023032406175412500_jlb10322-cit-0082","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0148-7","article-title":"Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma?","volume":"4","author":"Amin","year":"2016","journal-title":"J ImmunoTher Cancer"},{"key":"2023032406175412500_jlb10322-cit-0083","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00280-015-2870-0","article-title":"Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma?","volume":"76","author":"Yamazaki","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2023032406175412500_jlb10322-cit-0084","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma?","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2023032406175412500_jlb10322-cit-0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-016-0194-1","article-title":"A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma?","volume":"4","author":"Brohl","year":"2016","journal-title":"J ImmunoTher Cancer"},{"key":"2023032406175412500_jlb10322-cit-0086","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma?","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"key":"2023032406175412500_jlb10322-cit-0087","doi-asserted-by":"crossref","first-page":"e0179431","DOI":"10.1371\/journal.pone.0179431","article-title":"Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy?","volume":"12","author":"Charych","year":"2017","journal-title":"PLoS ONE"},{"key":"2023032406175412500_jlb10322-cit-0088","article-title":"Updated PIVOT-02 results demonstrate durable responses in advanced melanoma patients treated with NKTR-214 + nivolumab?","volume-title":"SITC Annual Meeting","author":"Diab","year":"2018"},{"key":"2023032406175412500_jlb10322-cit-0089","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer?","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"2023032406175412500_jlb10322-cit-0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2015.01.024","article-title":"ImmTACs for targeted cancer therapy: why, what, how, and which?","volume":"67","author":"Oates","year":"2015","journal-title":"Mol Immunol"},{"key":"2023032406175412500_jlb10322-cit-0091","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/imm.12779","article-title":"Polyfunctional response by ImmTAC (IMCgp100) redirected CD8 +and CD4 +T cells?","volume":"152","author":"Boudousquie","year":"2017","journal-title":"Immunology"},{"key":"2023032406175412500_jlb10322-cit-0092","article-title":"Safety, efficacy and biology of the gp100 TCR-?","volume-title":"SITC Annual Meeting","author":"Carvajal","year":"2017"},{"key":"2023032406175412500_jlb10322-cit-0093","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody?","volume":"25","author":"Vonderheide","year":"2007","journal-title":"JCO"},{"key":"2023032406175412500_jlb10322-cit-0094","doi-asserted-by":"crossref","first-page":"CT137","DOI":"10.1158\/1538-7445.AM2015-CT137","article-title":"Abstract CT137: combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma?","volume":"75","author":"Bajor","year":"2015","journal-title":"Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0095","doi-asserted-by":"crossref","first-page":"e23033","DOI":"10.4161\/onci.23033","article-title":"Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors?","volume":"2","author":"Vonderheide","year":"2013","journal-title":"OncoImmunology"},{"key":"2023032406175412500_jlb10322-cit-0096","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1084\/jem.20121190","article-title":"Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of eomesodermin?","volume":"210","author":"Curran","year":"2013","journal-title":"J Exp Med"},{"key":"2023032406175412500_jlb10322-cit-0097","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1158\/0008-5472.CAN-05-2128","article-title":"Combination therapy with Anti\u2013CTL antigen-4 and Anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity?","volume":"66","author":"Kocak","year":"2006","journal-title":"Cancer Research"},{"key":"2023032406175412500_jlb10322-cit-0098","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1158\/1078-0432.CCR-17-1922","article-title":"Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in patients with advanced cancer?","volume":"24","author":"Segal","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0099","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-17-1243","article-title":"Phase Ib study of utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors?","volume":"23","author":"Tolcher","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0100","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.4049\/jimmunol.0804211","article-title":"Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells?","volume":"182","author":"Grosso","year":"2009","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0101","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.4049\/jimmunol.168.8.3874","article-title":"Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)?","volume":"168","author":"Andreae","year":"2002","journal-title":"J Immunol"},{"key":"2023032406175412500_jlb10322-cit-0102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-12-97","article-title":"MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a phase I trial?","volume":"12","author":"Romano","year":"2014","journal-title":"J Transl Med"},{"key":"2023032406175412500_jlb10322-cit-0103","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1158\/1535-7163.MCT-14-0290","article-title":"Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma?","volume":"13","author":"Ilieva","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"2023032406175412500_jlb10322-cit-0104","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition?","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0105","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1172\/JCI45138","article-title":"Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs?","volume":"122","author":"Gupta","year":"2012","journal-title":"J Clin Invest"},{"key":"2023032406175412500_jlb10322-cit-0106","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia?","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"2023032406175412500_jlb10322-cit-0107","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","article-title":"CD8+ T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1?","volume":"72","author":"Fourcade","year":"2012","journal-title":"Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0362-6","article-title":"An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0?","volume":"6","author":"Sullivan","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"2023032406175412500_jlb10322-cit-0109","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting?","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"2023032406175412500_jlb10322-cit-0110","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion?","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"2023032406175412500_jlb10322-cit-0111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity?","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"2023032406175412500_jlb10322-cit-0112","first-page":"248","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade?","volume":"18","author":"Charoentong","year":"2017","journal-title":"CellReports"},{"key":"2023032406175412500_jlb10322-cit-0113","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"The \u201ccancer immunogram.\u201d?","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"2023032406175412500_jlb10322-cit-0114","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma?","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2023032406175412500_jlb10322-cit-0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-016-0705-4","article-title":"Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set?","volume":"14","author":"Roszik","year":"2016","journal-title":"BMC Medicine"},{"key":"2023032406175412500_jlb10322-cit-0116","doi-asserted-by":"crossref","first-page":"E7759","DOI":"10.1073\/pnas.1609376113","article-title":"Density of immunogenic antigens does not explain the presence or absence of the T-cell\u2013inflamed tumor microenvironment in melanoma?","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023032406175412500_jlb10322-cit-0117","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma?","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"key":"2023032406175412500_jlb10322-cit-0118","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma?","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"2023032406175412500_jlb10322-cit-0119","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma?","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"2023032406175412500_jlb10322-cit-0120","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma?","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"2023032406175412500_jlb10322-cit-0121","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma?","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"2023032406175412500_jlb10322-cit-0122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation?","volume":"8","author":"Sade-Feldman","year":"2017","journal-title":"Nat Commun"},{"key":"2023032406175412500_jlb10322-cit-0123","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1158\/0008-5472.CAN-16-0008","article-title":"Melanoma lesions independently acquire T-cell resistance during metastatic latency?","volume":"76","author":"Zhao","year":"2016","journal-title":"Cancer Research"},{"key":"2023032406175412500_jlb10322-cit-0124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-0990-x","article-title":"Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients?","volume":"14","author":"Seremet","year":"2016","journal-title":"J Transl Med"},{"key":"2023032406175412500_jlb10322-cit-0125","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy?","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"2023032406175412500_jlb10322-cit-0126","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-17-3008","article-title":"Prevalent homozygous deletions of type I interferon and defensin genes in human cancers associate with immunotherapy resistance?","volume":"24","author":"Ye","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0127","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1200\/JCO.2012.44.3762","article-title":"Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy?","volume":"31","author":"Ulloa-Montoya","year":"2013","journal-title":"JCO"},{"key":"2023032406175412500_jlb10322-cit-0128","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00262-011-1172-6","article-title":"An immune-active tumor microenvironment favors clinical response to ipilimumab?","volume":"61","author":"Ji","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"2023032406175412500_jlb10322-cit-0129","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade?","volume":"6","author":"Chen","year":"2016","journal-title":"Cancer Discov"},{"key":"2023032406175412500_jlb10322-cit-0130","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance?","volume":"9","author":"Roh","year":"2017","journal-title":"Sci Transl Med"},{"key":"2023032406175412500_jlb10322-cit-0131","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/ng.3677","article-title":"Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy?","volume":"48","author":"Riaz","year":"2016","journal-title":"Nat Genet"},{"key":"2023032406175412500_jlb10322-cit-0132","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1083\/jcb.200508064","article-title":"Serpin squamous cell carcinoma antigen inhibits UV-induced apoptosis via suppression of c-JUN NH 2-terminal kinase?","volume":"172","author":"Katagiri","year":"2006","journal-title":"J Cell Biol"},{"key":"2023032406175412500_jlb10322-cit-0133","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/labinvest.2016.126","article-title":"Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity?","volume":"97","author":"Bresler","year":"2016","journal-title":"Lab Invest"},{"key":"2023032406175412500_jlb10322-cit-0134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0612-6","article-title":"Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma?","volume":"11","author":"De Santo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2023032406175412500_jlb10322-cit-0135","doi-asserted-by":"crossref","first-page":"12032","DOI":"10.1200\/jco.2006.24.18_suppl.12032","article-title":"Recombinant arginase as a novel anti-melanoma agent?","volume":"24","author":"Hsueh","year":"2006","journal-title":"JCO"},{"key":"2023032406175412500_jlb10322-cit-0136","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature23477","article-title":"Identification of essential genes for cancer immunotherapy?","volume":"548","author":"Patel","year":"2017","journal-title":"Nature"},{"key":"2023032406175412500_jlb10322-cit-0137","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target?","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"key":"2023032406175412500_jlb10322-cit-0138","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.aao1710","article-title":"A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing?","volume":"359","author":"Pan","year":"2018","journal-title":"Science"},{"key":"2023032406175412500_jlb10322-cit-0139","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4161\/epi.5.6.12315","article-title":"SWItching on the transcriptional circuitry in melanoma?","volume":"5","author":"Vinod Saladi","year":"2014","journal-title":"Epigenetics"},{"key":"2023032406175412500_jlb10322-cit-0140","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi?","volume":"33","author":"Pollock","year":"2002","journal-title":"Nat Genet"},{"key":"2023032406175412500_jlb10322-cit-0141","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2007.12.032","article-title":"Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7?","volume":"132","author":"Wajapeyee","year":"2008","journal-title":"Cell"},{"key":"2023032406175412500_jlb10322-cit-0142","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1158\/1078-0432.CCR-09-1135","article-title":"Loss of SNF5 expression correlates with poor patient survival in melanoma?","volume":"15","author":"Lin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2023032406175412500_jlb10322-cit-0143","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity?","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"2023032406175412500_jlb10322-cit-0144","doi-asserted-by":"crossref","DOI":"10.1172\/JCI95351","article-title":"\u03b2-Catenin\u2013mediated immune evasion pathway frequently operates in primary cutaneous melanomas?","volume-title":"JCI","author":"Nsengimana","year":"2018"},{"key":"2023032406175412500_jlb10322-cit-0145","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy?","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"2023032406175412500_jlb10322-cit-0146","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy?","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"2023032406175412500_jlb10322-cit-0147","doi-asserted-by":"crossref","first-page":"108786","DOI":"10.18632\/oncotarget.22150","article-title":"Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3?","volume":"8","author":"Buart","year":"2017","journal-title":"Oncotarget"},{"key":"2023032406175412500_jlb10322-cit-0148","first-page":"441","article-title":"Computational genomics tools for dissecting tumour\u2013immune cell interactions?","volume":"17","author":"Hackl","year":"2016","journal-title":"Nature"},{"key":"2023032406175412500_jlb10322-cit-0149","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles?","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"2023032406175412500_jlb10322-cit-0150","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.immuni.2015.12.006","article-title":"Compendium of immune signatures identifies conserved and species-specific biology in response to inflammation?","volume":"44","author":"Godec","year":"2016","journal-title":"Immunity"},{"key":"2023032406175412500_jlb10322-cit-0151","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/ni1008-1091","article-title":"The Immunological Genome Project: networks of gene expression in immune cells?","volume":"9","author":"Heng","year":"2008","journal-title":"Nat Immunol"},{"key":"2023032406175412500_jlb10322-cit-0152","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders?","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2023032406175412500_jlb10322-cit-0153","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.cell.2017.06.016","article-title":"IFN\u03b3-Dependent tissue-immune homeostasis is co-opted in the tumor microenvironment?","volume":"170","author":"Nirschl","year":"2017","journal-title":"Cell"}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2FJLB.MR0618-241RR","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/JLB.MR0618-241RR","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/JLB.MR0618-241RR","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/105\/5\/915\/49496730\/jlb10322.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/105\/5\/915\/49496730\/jlb10322.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T06:29:01Z","timestamp":1679639341000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/105\/5\/915\/6935681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":153,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,1,30]]},"published-print":{"date-parts":[[2019,4,19]]}},"URL":"https:\/\/doi.org\/10.1002\/jlb.mr0618-241rr","relation":{},"ISSN":["1938-3673","0741-5400"],"issn-type":[{"value":"1938-3673","type":"electronic"},{"value":"0741-5400","type":"print"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,1,30]]}}}